

# Reduced systemic bicyclo-prostaglandin-E<sub>2</sub> and cyclooxygenase-2 gene expression are associated with inefficient erythropoiesis and enhanced uptake of hemozoin in children with severe malarial anemia

Samuel B. Anyona,<sup>1,2,3</sup> Prakasha Kempaiah,<sup>4</sup> Evans Raballah,<sup>1,2</sup> Gregory C. Davenport,<sup>4</sup> Tom Were,<sup>1,5</sup> Stephen N. Konah,<sup>1</sup> John M. Vulule,<sup>6</sup> James B. Hittner,<sup>7</sup> Charity W. Gichuki,<sup>2</sup> John M. Ong'echa,<sup>1</sup> and Douglas J. Perkins<sup>1,4</sup>

**In holoendemic *Plasmodium falciparum* transmission areas, severe malaria primarily occurs in children aged <48 months and manifests as severe malarial anemia [SMA; hemoglobin (Hb) < 6.0 g/dL]. Induction of high levels of prostaglandin-E<sub>2</sub> (PGE<sub>2</sub>) through inducible cyclooxygenase-2 (COX-2) is an important host-defense mechanism against invading pathogens. We have previously shown that COX-2-derived PGE<sub>2</sub> levels are reduced in children residing in hyperendemic transmission regions with cerebral malaria and in those with mixed sequelae of anemia and hyperparasitemia. Our in vitro studies further demonstrated that reduced PGE<sub>2</sub> was due to downregulation of COX-2 gene products following phagocytosis of malarial pigment (hemozoin, PfHz). However, as COX-2-PGE<sub>2</sub> pathways and the impact of naturally acquired PfHz on erythropoietic responses have not been determined in children with SMA, plasma and urinary bicyclo-PGE<sub>2</sub>/creatinine and leukocytic COX-2 transcripts were determined in parasitized children (<36 months) stratified into SMA (*n* = 36) and non-SMA (Hb ≥ 6.0 g/dL; *n* = 38). Children with SMA had significantly reduced plasma (*P* = 0.001) and urinary (*P* < 0.001) bicyclo-PGE<sub>2</sub>/creatinine and COX-2 transcripts (*P* = 0.007). There was a significant positive association between Hb and both plasma (*r* = 0.363, *P* = 0.002) and urinary (*r* = 0.500, *P* = 0.001) bicyclo-PGE<sub>2</sub>/creatinine. Furthermore, decreased systemic bicyclo-PGE<sub>2</sub>/creatinine was associated with inefficient erythropoiesis (i.e., reticulocyte production index; RPI < 2.0, *P* = 0.026). Additional analyses demonstrated that plasma (*P* = 0.031) and urinary (*P* = 0.070) bicyclo-PGE<sub>2</sub>/creatinine and COX-2 transcripts (*P* = 0.026) progressively declined with increasing concentrations of naturally acquired PfHz by monocytes. Results presented here support a model in which reduced COX-2-derived PGE<sub>2</sub>, driven in part by naturally acquired PfHz by monocytes, promotes decreased erythropoietic responses in children with SMA. Am. J. Hematol. 87:782–789, 2012. © 2012 Wiley Periodicals, Inc.**

## Introduction

Approximately 85% of the fatalities from malaria occur in children aged less than 5 years in sub-Saharan Africa and are due to infection with *Plasmodium falciparum* [1]. Severe malaria can present as single or overlapping clinical features, including severe anemia, metabolic acidosis, respiratory distress, acute renal failure, hypoglycemia, hyperparasitemia, and cerebral malaria (CM) [2]. In holoendemic *P. falciparum* transmission regions such as Siaya, western Kenya, severe malarial anemia (SMA) is the most common cause of malaria-associated morbidity and mortality and primarily occurs in children aged less than 4 years [3–5].

The etiology of SMA can occur through one (or a combination) of pathophysiological mechanisms, including lysis of infected and uninfected red blood cells (RBCs) [6–9], splenic sequestration of RBCs [10], and dyserythropoiesis and suppression of erythropoiesis [11,12]. In addition, the pathogenesis of SMA is frequently complicated by coinfections with HIV-1, bacteremia, upper respiratory tract viral infections, and hookworm infections [13–19]. In infants and young children residing in holoendemic regions, some or all of these factors, along with constant, year-round malaria transmission can culminate in chronically low hemoglobin (Hb) concentrations. Our recent study showed that insufficient erythropoiesis was important in the etiology of SMA in children in the Siaya community [20].

A central feature that mediates the pathogenesis of SMA is the release of soluble mediators of inflammation (e.g., cytokines, chemokines, and effector molecules) as part of the host-immune response [21]. During a malaria infection, this process is largely driven by phagocytosis of malarial pigment (hemozoin, PfHz) by monocytes, neutrophils, and

resident macrophages [21]. PfHz is formed during the intra-erythrocytic asexual replication cycle in which *P. falciparum* metabolizes host Hb as a source of amino acids [22,23]. The remaining iron-rich heme portion (i.e., ferriprotoporphyrin IX) is then aggregated into an insoluble product, PfHz, by the action of heme polymerase [24–29]. Monocytes, neutrophils, and macrophages acquire PfHz through phagocytosis of parasitized RBCs and by taking up free PfHz released on lysis of infected RBCs [21].

<sup>1</sup>Laboratories of Parasitic and Viral Diseases, Centre for Global Health Research, Kenya Medical Research Institute, University of New Mexico, Kisumu, Kenya; <sup>2</sup>Department of Biochemistry and Biotechnology, School of Pure and Applied Sciences, Kenyatta University, Nairobi, Kenya; <sup>3</sup>Department of Medical Biochemistry, School of Medicine, Maseno University, Maseno, Kenya; <sup>4</sup>Center for Global Health, University of New Mexico, Albuquerque, New Mexico; <sup>5</sup>Department of Pathology, School of Health Sciences, Kenyatta University, Nairobi, Kenya; <sup>6</sup>Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya; <sup>7</sup>Department of Psychology, College of Charleston, Charleston, South Carolina

Conflict of interest: Nothing to report

\*Correspondence to: Douglas Jay Perkins, PhD, Director, Center for Global Health, Department of Internal Medicine, MSC10-5550 1, University of New Mexico, Albuquerque, NM 87131. E-mail: dperkins@salud.unm.edu

Contract grant sponsor: National Institutes of Health (NIH); Contract grant number: 1 R01A151305.

Contract grant sponsor: Fogarty International Center (FIC); Contract grant number: 1 D43TW05884.

Received for publication 16 April 2012; Accepted 26 April 2012

Am. J. Hematol. 87:782–789, 2012.

Published online 6 May 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/ajh.23253

Previous *in vitro* studies from our laboratories showed that ingestion of *PfHz* by blood mononuclear cells caused suppression of prostaglandin-E<sub>2</sub> (PGE<sub>2</sub>) through suppression of cyclooxygenase-2 (COX-2; prostaglandin endoperoxide H<sub>2</sub> synthase-2) gene products [30]. COX-2 is an inducible enzyme predominantly expressed in cells involved in inflammatory reactions, such as macrophages, endothelial cells, and fibroblasts [31–33]. Increased expression of COX-2 by proinflammatory mediators generates high levels of PGE<sub>2</sub> production as part of the host-immune response to infections [34–39]. Because PGE<sub>2</sub> and its metabolites are unstable *in vivo*, levels of PGE<sub>2</sub> are measured as bicyclo-PGE<sub>2</sub> (the stable breakdown product of PGE<sub>2</sub> and 13,14-dihydro-15-keto PGE<sub>2</sub>) and can be expressed in a ratio with creatinine levels to account for differences in hydration status [40,41].

Our previous studies in Gabonese children with *P. falciparum* malaria demonstrated an inverse relationship between circulating bicyclo-PGE<sub>2</sub>/creatinine, peripheral blood mononuclear cell COX-2 mRNA and protein [42] expression, and disease severity. Consistent with these results, our follow-up study in Tanzanian children with CM demonstrated that systemic levels of bicyclo-PGE<sub>2</sub>/creatinine decreased with increasing disease severity such that children with neurological sequelae and/or those who eventually died had the lowest bicyclo-PGE<sub>2</sub>/creatinine levels [43]. Furthermore, we have shown that high levels of naturally acquired *PfHz* were associated with decreased PGE<sub>2</sub> production in cultured intervillous blood mononuclear cells from Kenyan women with placental malaria [44]. Taken together, these results demonstrate that suppression of COX-2-derived PGE<sub>2</sub> is associated with enhanced severity of falciparum malaria.

Although unexplored in children with SMA, the COX-2-PGE<sub>2</sub> pathway may be important because COX-2 plays an important role in erythroid maturation [45–49], and PGE<sub>2</sub> can cause reduced RBC deformability [50] and volume [51]. As such, we examined plasma and urinary levels of bicyclo-PGE<sub>2</sub>/creatinine and leukocytic COX-2 transcripts in extensively phenotyped children with *P. falciparum* infections (age < 36 months; *n* = 74) stratified into non-SMA (Hb ≥ 6.0 g/dL) and SMA (Hb < 6.0 g/dL). As coinfection with HIV-1 and/or bacteremia alters the host-immune response in children with SMA [16,18], all coinfecting children were excluded from the study. The current study explores the relationship between the COX-2-PGE<sub>2</sub> pathway and erythropoiesis and the impact of naturally acquired *PfHz* on COX-2-derived plasma and urinary levels of bicyclo-PGE<sub>2</sub>/creatinine.

## Materials and Methods

**Study site.** The study was carried out at the Siaya District Hospital (SDH) in western Kenya. Falciparum malaria prevalence more than a decade ago was 83% in children aged between 1 and 4 years [52] and has remained stable with an increase in pediatric malaria admissions, particularly from mid-2006 to date [53]. Consequently, SMA remains a significant contributor to hospital-associated morbidity and mortality [3]. Details of the study site and malarial anemia in the pediatric population are described in our previous report [4].

**Study participants.** Children with malaria (*n* = 74) of both genders [age, <36 months; male (*n* = 45), female (*n* = 29)] visiting SDH for their first hospital contact were enrolled, after obtaining written informed consent from the parent/legal guardian, to participate in the study. Hb levels (g/dL) were used to group children with falciparum malaria into two groups, (i) non-SMA (Hb ≥ 6.0 g/dL, *n* = 38) and (ii) SMA (Hb < 6.0 g/dL, *n* = 36), based on the description of anemia determined by greater than 14,000 longitudinal Hb measurements in age- and gender-matched children from the same geographic location [54]. In addition, to place the current findings into a global context, results are also presented for children grouped according to the World Health Organization (WHO) definition of SMA: non-SMA (Hb ≥ 5.0 g/dL, *n* = 52) and SMA (Hb < 5.0 g/dL, *n* = 22) [55]. Children were excluded from the study if

they had mixed malaria species infections, HIV-1, bacteremia, prior hospitalization (for any reason), antimalarial and/or antipyretic treatment within 2 weeks prior to enrollment, and CM. Patients were treated and provided supportive care according to the Ministry of Health-Kenya guidelines. The study was approved by the Ethics Committees of the Kenya Medical Research Institute and the University of New Mexico Institutional Review Board.

**Clinical laboratory evaluation.** Venipuncture blood samples (<3.0 mL) were collected from enrolled participants before any treatment interventions. Complete blood counts were determined using the Beckman Coulter A<sup>T</sup> diff2<sup>TM</sup> (Beckman-Coulter Corporation, Miami, FL). Asexual malaria trophozoites in thick and thin peripheral blood smears and reticulocyte count were determined according to previous methods [16]. As there are known cofounders of anemia in this malaria endemic region, coinfections (i.e., HIV-1 and bacteremia) and sickle-cell status were determined according to our previous methods [16]. Parents/guardians of the study participants received pretest and post-test HIV/AIDS counseling and provided informed consent.

**Determination of bicyclo-PGE<sub>2</sub> and creatinine levels.** To measure bicyclo-PGE<sub>2</sub> levels in plasma and urine samples, a commercial prostaglandin E metabolite (PGEM) kit (Cayman Chemical Company, MI) was used according to the manufacturer's instructions. Because PGE<sub>2</sub> has a high turnover rate in peripheral circulation, the PGE<sub>2</sub> metabolites (13,14-dihydro-15-keto PGE<sub>2</sub> and 13,14-dihydro-15-keto PGE<sub>2</sub>) were converted to single derivatives (stable end product bicyclo-PGE<sub>2</sub>). Briefly, 250 μL of either plasma or urine samples were precipitated in 95% ethanol. Organic solvents were eliminated by passing samples through C-18 (containing 500 mg sorbent) solid-phase extraction cartridges (Supelco Analytical, PA) coated with octadecyl silica as the packing material. Samples were eluted from the columns in 5 mL ethyl acetate (Sigma-Aldrich, MO) containing 1% methanol and evaporated to dryness under a stream of nitrogen gas. Samples were then resuspended in 500 μL of commercial 1× enzyme immunoassay (EIA) buffer (Cayman Chemicals Company). Resulting PGE<sub>2</sub> and the intermediary metabolites were derivatized overnight at 37°C to bicyclo-PGE<sub>2</sub> in 150 μL of 1 M carbonate buffer, and thereafter, 200 μL of 1 M phosphate buffer and 150 μL of 1× EIA buffer were added (Cayman Chemicals Company). Bicyclo-PGE<sub>2</sub> levels were then determined by quantitative sandwich EIA as described by the manufacturer (Cayman Chemicals Company). Sensitivity of detection for bicyclo-PGE<sub>2</sub> levels was ≥2 pg/mL.

Plasma and urine creatinine levels were determined using the creatinine determination kit (Cayman Chemicals Company). Plasma and urine samples were diluted 1:20 with ultrapure water, and creatinine was quantified by enzyme-linked immunosorbent assay according to the manufacturer's protocol (Cayman Chemicals Company).

**Total RNA isolation and COX-2 gene expression analyses.** Total RNA was isolated from cryopreserved white blood cell (WBC) pellets [preserved in commercial RNAlater RNA stabilization reagent (Qiagen, CA)] by the acid guanidinium thiocyanate-phenol-chloroform extraction method [56]. Resulting RNA concentrations were determined by measuring absorbance (*A* = 260 nm/*A* = 280 nm) and the quality assessed by checking for contaminating salts and proteins at *A* = 230 nm/*A* = 320 nm, using a GeneQuant pro spectrophotometer (Biochrom, Cambridge, England).

Reverse transcription (RT) of RNA to complementary DNA (cDNA) was performed using the high-capacity cDNA RT kit (Applied Biosystems, CA) according to the manufacturer's protocol. Briefly, 2 μg of total RNA was reverse transcribed in a 20 μL reaction mix, containing as final concentrations, 1× RT buffer, 1 mM dNTP mix, 1× RT random hexamers, 5 U MultiScribe<sup>TM</sup> reverse transcriptase, and 20 U RNase inhibitor. Reverse transcription steps were performed using a GeneAmp PCR system 9700 (Applied Biosystems, CA), with the thermal cycler conditions set at an initial 65°C, hold for 5 min, followed by a 25°C hold for 10 min, 48°C hold for 45 min, and a final enzyme denaturing step at 95°C for 5 min.

To quantify COX-2 mRNA expression, the resulting cDNA was amplified for 30 cycles using oligonucleotides spanning the exon–intron junction in the COX-2 gene, with the sense (5'-GAC TCC CTT GGG TGT CAA AGG TAA-3') and antisense (5'-GTG AAG TGC TGG GCA AAG AAT G-3') sequence used to generate a 138-bp product. The glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) gene (endogenous control) was amplified to yield a 381-bp fragment in a 30-cycle reaction using the following oligo sequences: sense (5'-CTA CTG GCG CTG CCA AGG CTG T-3') and antisense (5'-GCC ATG AGG TCC ACC ACC CTG T-3'). Resulting polymerase chain reaction (PCR) fragments were resolved on a 2% agarose gel stained with 0.5 mg/mL ethidium bromide (Sigma Chemicals, MO) and visualized under UV light (Spectrolite<sup>®</sup> Corporation, NY). Electrophoretic gel films were analyzed

**TABLE I. Clinical, demographic, and laboratory characteristics of the study participants**

Characteristics	Non-SMA (Hb ≥ 6.0 g/dL)	SMA (Hb < 6.0 g/dL)	P value
Number of participants	38	36	
Gender, n (%)			
Male	24 (63.2)	21 (58.3)	0.671 <sup>a</sup>
Female	14 (36.8)	15 (41.7)	
Age (months)	12.5 (13.0)	8.0 (7.0)	<b>0.010<sup>b</sup></b>
Admission temperature (°C)	37.6 (2.0)	37.5 (2.0)	0.637 <sup>b</sup>
Glucose (mmol/L)	5.6 (2.0)	5.6 (1.0)	0.278 <sup>b</sup>
<b>Hematological indices</b>			
Hemoglobin (g/dL)	8.0 (2.6)	4.8 (1.5)	<b>&lt;0.001<sup>b</sup></b>
Hematocrit (%)	24.2 (7.1)	14.7 (4.4)	<b>&lt;0.001<sup>b</sup></b>
RBCs (×10 <sup>9</sup> μL <sup>-1</sup> )	3.5 (1.4)	2.1 (0.9)	<b>&lt;0.001<sup>b</sup></b>
RDW (%)	20.6 (2.8)	23.4 (5.8)	<b>0.008<sup>b</sup></b>
MCV (fL)	70.8 (14.0)	70.4 (11.0)	0.516 <sup>b</sup>
MCH (fL per cell)	23.0 (5.1)	22.6 (3.8)	0.390 <sup>b</sup>
MCHC (g/dL)	32.6 (2.1)	32.2 (2.0)	0.660 <sup>b</sup>
WBCs (×10 <sup>9</sup> L <sup>-1</sup> )	9.7 (6.4)	13.9 (11.6)	<b>0.035<sup>b</sup></b>
Lymphocytes (×10 <sup>9</sup> μL <sup>-1</sup> )	5.3 (2.6)	6.9 (5.3)	0.066 <sup>b</sup>
Monocytes (×10 <sup>9</sup> μL <sup>-1</sup> )	1.0 (0.8)	1.4 (1.1)	0.065 <sup>b</sup>
Granulocytes (×10 <sup>9</sup> μL <sup>-1</sup> )	3.6 (3.0)	5.8 (6.0)	<b>0.015<sup>b</sup></b>
Platelets (×10 <sup>9</sup> μL <sup>-1</sup> )	159.0 (132.0)	145.5 (76.0)	0.764 <sup>b</sup>
<b>Erythropoietic indices</b>			
Reticulocyte count (%)	1.9 (3.1)	4.4 (5.6)	<b>0.006<sup>a</sup></b>
Absolute reticulocyte number (ARN) (×10 <sup>9</sup> L <sup>-1</sup> )	43.8 (78.2)	36.7 (54.2)	0.070 <sup>b</sup>
Reticulocyte production index (RPI) (μL <sup>-1</sup> )	1.0 (2.0)	0.9 (2.0)	0.165 <sup>b</sup>
RPI < 2, n (%)	31 (47.0)	35 (53.0)	<b>0.030<sup>a</sup></b>
Erythrophagocytosis (%)	2.5 (6.0)	4.0 (12.0)	<b>0.036<sup>b</sup></b>
Erythrophagocytosis (×10 <sup>3</sup> μL <sup>-1</sup> )	0.02 (0.07)	0.05 (0.13)	0.140 <sup>b</sup>
<b>Parasitological indices</b>			
Parasite density (MPS μL <sup>-1</sup> )	8717.6 (34823.4)	11320.8 (31339.1)	0.875 <sup>b</sup>
Geomean parasitemia (μL <sup>-1</sup> )	9358.7	9787.5	—
HDP (≥10,000 parasites per microliter), n (%)	19 (50.0)	19 (53.0)	0.811 <sup>a</sup>
<b>Genetic variants</b>			
Sickle-cell trait, n (%)	5 (13.2)	5 (13.9)	0.927 <sup>a</sup>
G6PD deficiency, n (%)	5 (13.2)	4 (11.1)	0.788 <sup>a</sup>
<b>Additional laboratory measures</b>			
Pigment containing monocytes (PCM), n (%)	11 (31.4)	24 (68.6)	<b>0.001<sup>a</sup></b>
Plasma creatinine (mg/dL)	0.3 (0.4)	0.6 (0.5)	<b>0.007<sup>b</sup></b>
Urinary creatinine (mg/dL)	32.1 (32.9)	42.8 (67.0)	<b>0.047<sup>b</sup></b>

Bold indicates a significant value of *P* < 0.050.

Data are presented as the median (interquartile range) unless otherwise noted. Parasitemic children (*n* = 74) were categorized according to a modified definition of SMA based on age-matched and geographically matched hemoglobin concentrations (i.e., Hb < 6.0 g/dL, with any density parasitemia) [54] into non-SMA (*n* = 38) and SMA (*n* = 36). However, for the determination of the absolute reticulocyte number (ARN) and the reticulocyte production index (RPI) in the clinical groups, six samples with missing data on reticulocyte count and/or hematocrit levels were excluded from analyses. As such, comparison of the erythropoietic indices between non-SMA (*n* = 37) and SMA (*n* = 31) was carried out on 68 children. ARN and RPI were calculated, based on previous procedures [19,60], as follows: reticulocyte index (RI) = (reticulocyte count × hematocrit)/30.7 (average hematocrit of children < 5 years of age in Siaya district); maturation factor (MF) = 1 + 0.05 (30.7 – hematocrit); RPI = RI/MF; ARN = (RI × RBC count per liter)/100. Erythrophagocytosis was determined in thin smear Giemsa-stained blood slides, with 100 monocytes counted per slide, and the number of monocytes/macrophages with phagocytosed RBCs expressed as a percentage of the total number of cells examined. In addition, erythrophagocytosis per microliter was estimated using the Coulter analyzer generated total monocyte counts. All subjects positive for HIV-1 or bacterial infections were excluded from the analyses.

Abbreviations: Hb, Hemoglobin; non-SMA, nonsevere malarial anemia (Hb ≥ 6.0 g/dL, with any density parasitemia); SMA, severe malarial anemia (Hb < 6.0 g/dL, with any density parasitemia) [54]; RDW, red cell distribution width; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MPS, malaria parasites; HDP, high-density parasitemia (MPS ≥ 10,000/μL).

<sup>a</sup> Statistical significance was determined by Pearson's  $\chi^2$  test.

<sup>b</sup> Statistical significance was determined by Mann-Whitney *U*-test.

using the ImageJ software [57] and PCR product mean band intensities were quantified. The COX-2 mRNA expression mean values (arbitrary units; AU) were normalized by expressing them relative to GAPDH mRNA mean values.

**Determination of pigment-containing monocytes, reticulocyte production index, and erythrophagocytosis.** Pigment-containing monocyte (PCM) levels were determined in thin Giemsa-stained blood smears,

with a total of 30 monocytes examined per slide, and the number of PCM expressed as a percentage of the total number of cells examined. Total PCM per microliter was calculated according to previous methods [58,59]. PCM levels were grouped as follows: PCM (–) = no pigment-containing monocytes; low = ≤10%; moderate = >10 and <26.7%; and high = ≥26.7% [19]. The RPI was similarly determined according to our previous methods [60,61]. To approximate the rates of erythrophagocytosis among the clinical groups, methanol-fixed Giemsa-stained thin blood smears were used, where 100 monocytes/macrophages were counted per slide, and the number of monocytes/macrophages with phagocytosed RBCs expressed as a percentage of the total number of cells examined. In addition, erythrophagocytosis per microliter was estimated using the Coulter analyzer generated total monocyte counts.

**Statistical analyses.** Analyses were performed with SPSS<sup>®</sup> statistical software package version 19 (IBM<sup>®</sup>, IL). Comparisons of demographic, clinical, and parasitological variables between the groups were computed using Pearson's  $\chi^2$  test and Mann-Whitney *U*-test. Relationships between plasma or urinary bicyclo-PGE<sub>2</sub>/creatinine levels and Hb concentrations were determined using Spearman's correlation coefficient. The relationship between plasma and urinary bicyclo-PGE<sub>2</sub>/creatinine levels and malaria clinical groups (and PCM levels) was examined using Mann-Whitney *U*-test for pairwise comparisons and Kruskal-Wallis tests for across group comparisons, respectively. COX-2 mRNA expression data were normalized by expressing COX-2 as a ratio over GAPDH (endogenous control) with comparisons between the non-SMA and SMA groups performed using Student's *t*-test. Comparison of COX-2/GAPDH across the various PCM groups was performed by ANOVA. Statistical significance was set at *P* ≤ 0.050.

**Results**

**Clinical and laboratory characteristics of study participants**

Parasitemic children (*n* = 74; <36 months) were grouped according to previously defined criterion [54] into non-SMA (Hb ≥ 6.0 g/dL; *n* = 38) and SMA (Hb < 6.0 g/dL; *n* = 36). The clinical, demographic, and laboratory characteristics of the participants are presented in Table I. Although the distribution of females and males in the clinical groups was comparable (*P* = 0.671), children with SMA were significantly younger (*P* = 0.010). Enrollment temperature (°C) and glucose (mmol/L) levels were comparable (*P* = 0.637 and *P* = 0.278, respectively) between the groups. Given the a priori classification of the clinical phenotypes, hematological indices, including median Hb levels (*P* < 0.001), hematocrit (*P* < 0.001), and total RBCs (*P* < 0.001), were significantly lower in children with SMA. The red cell distribution width (RDW; *P* = 0.008) and WBC (*P* = 0.035) were higher in the SMA group. However, the mean corpuscular volume (MCV; *P* = 0.516), mean corpuscular hemoglobin (*P* = 0.390), and mean cell hemoglobin concentration (*P* = 0.660) were comparable between the groups. The significant elevation in the RDW in the SMA group in the context of a “normal” (non-significant change) in the MCV may suggest the beginning stages of a vitamin B12 or folic acid deficiency and/or the initial stages of iron deficiency anemia. In addition, the total lymphocyte (*P* = 0.066) and monocyte (*P* = 0.065) counts were marginally increased in children with SMA. Although the total granulocyte counts were higher in children with SMA (*P* = 0.015), platelet counts were comparable between the two groups (*P* = 0.764). As reticulocyte counts and hematocrit levels are required to determine the absolute reticulocyte number (ARN) and reticulocyte production index (RPI), children (*n* = 6) with missing data on these variables were excluded from analyses. Although reticulocyte counts were significantly higher among children with SMA (*P* = 0.006), the ARN (*P* = 0.070) and RPI (*P* = 0.165) were marginally lower in the SMA group. However, insufficient erythropoiesis (i.e., RPI < 2) was significantly more frequent in children with SMA (*P* = 0.030). Furthermore, erythrophagocytosis (% and μL<sup>-1</sup>) was elevated in children with SMA (*P* = 0.036 and *P* = 0.140, respectively) relative to those with non-SMA, suggesting increased destruction of erythro-




Figure 1. Bicyclo-PGE<sub>2</sub>/creatinine concentrations and COX-2 transcripts in children with and without SMA. Concentrations of bicyclo-PGE<sub>2</sub>/creatinine and COX-2 transcripts in children with non-SMA (Hb  $\geq$  6.0 g/dL, with any density parasitemia) and SMA (Hb < 6.0 g/dL, with any density parasitemia). A: Plasma bicyclo-PGE<sub>2</sub>/creatinine levels (pg/mg/mL) in the non-SMA ( $n = 38$ ) and SMA ( $n = 36$ ) groups. Differences between the groups were determined by Mann-Whitney *U*-test. B: Urinary bicyclo-PGE<sub>2</sub>/creatinine levels (pg/mg/mL) in the non-SMA ( $n = 22$ ) and SMA ( $n = 22$ ) groups. Differences between the groups were determined by Mann-Whitney *U*-test. C: Semiquantitative COX-2 transcript expression in children presenting with either non-SMA ( $n = 9$ ) or SMA ( $n = 14$ ). COX-2 mRNA expression mean values (arbitrary units, AU) were normalized by expression over GAPDH mRNA mean values (endogenous control). Differences between the groups were determined by Student's *t*-test.

cytes as a potential cause of reduced Hb concentrations in children with SMA. Peripheral parasite densities ( $P = 0.875$ ), geometric mean parasitemia, and high-density parasitemia ( $\geq 10,000/\mu\text{L}$ ;  $P = 0.811$ ) did not differ between the groups. In addition, distribution of sickle-cell trait ( $P = 0.927$ ) and G6PD deficiency ( $P = 0.788$ ) were comparable between the groups. Children with SMA had a higher prevalence of PCMs ( $P = 0.001$ ) and higher plasma and urinary creatinine levels when compared with those with non-SMA ( $P = 0.007$  and  $P = 0.047$ , respectively).

#### Bicyclo-PGE<sub>2</sub> and COX-2 transcripts are suppressed in children with SMA

To investigate the association between in vivo systemic PGE<sub>2</sub> concentrations, COX-2 gene expression, and clinical outcomes, we examined plasma ( $n = 74$ ) and urinary ( $n = 44$ ) bicyclo-PGE<sub>2</sub>/creatinine levels (pg/mg/mL) and WBC COX-2 transcripts in the two groups. To account for potential differences in hydration status, bicyclo-PGE<sub>2</sub> (pg/mL) levels were expressed per unit creatinine (mg/dL). Children with SMA had significantly reduced plasma ( $P = 0.001$ ; Fig. 1A) and urinary ( $P < 0.001$ ; Fig. 1B) bicyclo-PGE<sub>2</sub>/creatinine levels relative to non-SMA. Consistent with these results, WBC COX-2 transcripts were significantly lower in the SMA group ( $n = 14$ ) relative to those with non-SMA ( $n = 9$ ,  $P = 0.007$ ; Fig. 1C).

On classification according to the WHO criteria [55], children with SMA (Hb < 5.0 g/dL) had significantly lower bicyclo-PGE<sub>2</sub>/creatinine levels in plasma ( $P = 0.004$ ) and urine ( $P = 0.011$ ). Similarly, COX-2 transcripts were also significantly reduced in the SMA group ( $n = 14$ ) when compared with children with non-SMA ( $n = 9$ ,  $P = 0.003$ ). Thus, reduced leukocytic COX-2 transcripts and lower systemic bicyclo-PGE<sub>2</sub>/creatinine levels are associated with more severe clinical manifestations of malaria.

Additional analyses were performed with the inclusion of healthy children to explore bicyclo-PGE<sub>2</sub>/creatinine

production in noninfected versus malaria-infected individuals. There was a significance across group difference in plasma bicyclo-PGE<sub>2</sub>/creatinine levels in healthy controls [median (interquartile range) 2,371 (8,576),  $n = 10$ ], children with non-SMA [3,667 (7,235),  $n = 38$ ], and those with SMA [2,122 (2,552),  $n = 36$ ,  $P = 0.005$ , Kruskal Wallis test). Additional post hoc analyses showed no difference in bicyclo-PGE<sub>2</sub>/creatinine levels between healthy controls and those with SMA ( $P = 0.236$ ). However, bicyclo-PGE<sub>2</sub>/creatinine levels were elevated in the non-SMA group when compared with healthy controls ( $P = 0.050$ ).

#### Suppression of bicyclo-PGE<sub>2</sub> is associated with insufficient erythropoiesis

Next, we determined the association between systemic bicyclo-PGE<sub>2</sub>/creatinine and Hb concentrations. These analyses revealed a significant positive correlation between Hb levels and bicyclo-PGE<sub>2</sub>/creatinine in both plasma ( $r = 0.363$ ,  $P = 0.002$ ; Fig. 2A) and urine ( $r = 0.500$ ,  $P = 0.001$ ; Fig. 2B). As children with SMA were younger than those with non-SMA [12.5 (13.0) vs. 8.0 (7.0) months], and the COX-2-PGE<sub>2</sub> pathway could (potentially) be affected by age, we examined the relationship between bicyclo-PGE<sub>2</sub>/creatinine and age. There was no relationship between age and bicyclo-PGE<sub>2</sub>/creatinine in either plasma ( $r = -0.079$ ,  $P = 0.503$ ) or urine ( $r = 0.168$ ,  $P = 0.287$ ) in parasitemic children. Additional analyses in children stratified according to disease severity (i.e., non-SMA and SMA) also failed to show a relationship between age and bicyclo-PGE<sub>2</sub>/creatinine in plasma and urine in the non-SMA ( $r = -0.075$ ,  $P = 0.653$  and  $r = -0.058$ ,  $P = 0.798$ , respectively) and SMA ( $r = -0.002$ ,  $P = 0.989$  and  $r = 0.094$ ,  $P = 0.687$ , respectively) groups.

To explore the relationship between PGE<sub>2</sub> and erythropoiesis, bicyclo-PGE<sub>2</sub>/creatinine levels were compared between individuals with insufficient erythropoiesis (RPI < 2.0) and those with appropriate (RPI  $\geq$  3.0) erythropoiesis




Figure 2. Relationship between bicyclo-PGE<sub>2</sub>/creatinine levels, hemoglobin concentrations, and reticulocyte production index. A: Relationship between plasma bicyclo-PGE<sub>2</sub>/creatinine (pg/mg/mL) and Hb concentrations (g/dL) in children with malaria (n = 74). Correlation coefficient (r) and statistical significance determined by Spearman's rank correlation test. B: Relationship between urinary bicyclo-PGE<sub>2</sub>/creatinine (pg/mg/mL) and Hb levels (g/dL) in children with malaria (n = 44). Correlation coefficient (r) and statistical significance determined by Spearman's rank correlation test. C: Plasma bicyclo-PGE<sub>2</sub>/creatinine (pg/mg/mL) in children with insufficient (RPI < 2.0) and appropriate (RPI ≥ 3.0) erythropoiesis. Differences between the groups were determined by Mann-Whitney U-test.

[60,61]. As shown in Fig. 2C, children with insufficient erythropoiesis (RPI < 2.0) had significantly lower plasma bicyclo-PGE<sub>2</sub>/creatinine levels when compared with those with appropriate erythropoiesis (RPI ≥ 3.0, P = 0.026). No significant differences in erythropoiesis were reflected for urinary bicyclo-PGE<sub>2</sub>/creatinine (P = 0.371), likely due to the small number of samples available (n = 3) in the RPI ≥ 3.0 group (data not presented).

**Suppression of bicyclo-PGE<sub>2</sub> and COX-2 transcripts is associated with increasing deposition of monocytic PfHz**

To investigate the impact of naturally acquired PfHz on COX-2-PGE<sub>2</sub> pathways, children were stratified according to the level (%) of PCM. With increasing levels of PCM, bicyclo-PGE<sub>2</sub>/creatinine concentrations progressively declined in plasma (P = 0.031; Fig. 3A) and urine (P = 0.070; Fig. 3B). When compared with the PCM (-) group, plasma bicyclo-PGE<sub>2</sub>/creatinine levels were significantly lower in the moderate (P = 0.050; Fig. 3A) and high (P = 0.013) PCM groups. Additional analyses of urinary bicyclo-PGE<sub>2</sub>/creatinine levels showed a significant decrease in children with moderate PCM when compared with the PCM (-) group (P = 0.029; Fig. 3B). Consistent with the results obtained for the systemic levels of bicyclo-PGE<sub>2</sub>, COX-2 transcripts decreased progressively with increasing deposition of PfHz in monocytes (P = 0.026; Fig. 3C). Pairwise analyses demonstrated a significant decrease in the moderate (P = 0.039) and high (P = 0.010) PCM groups when compared with the PCM (-) group. Taken together, these results show that increasing deposition of PfHz in monocytes is associated with reduced systemic bicyclo-PGE<sub>2</sub> production and leukocytic COX-2 gene expression.

**Discussion**

The primary objective of this study was to determine the relationship between the COX-2-PGE<sub>2</sub> pathway, erythropoi-

esis, and naturally acquired monocytic PfHz. As such, we examined the COX-2-PGE<sub>2</sub> pathway in a pediatric population living in a *P. falciparum* holoendemic region of western Kenya in which the primary manifestation of severe malaria is SMA [3,4,16]. To eliminate the potential influence of coinfection on the host-immune response, all coinfecting children were excluded from the study. Results presented here demonstrate that systemic bicyclo-PGE<sub>2</sub>/creatinine and WBC COX-2 mRNA transcripts were significantly suppressed in children with SMA. Consistent with this finding, there was a positive correlation between Hb concentrations and both plasma and urinary bicyclo-PGE<sub>2</sub>/creatinine levels with decreased bicyclo-PGE<sub>2</sub>/creatinine being associated with inappropriate erythropoiesis (i.e., RPI < 2.0). Furthermore, suppression of systemic bicyclo-PGE<sub>2</sub>/creatinine and COX-2 transcripts were associated with increasing levels of monocytic PfHz acquired during the acute infection.

Our previous studies [42–44] have consistently shown that COX-2-derived PGE<sub>2</sub> production is suppressed during severe malaria infections. These results are consistent with a study in adults (15–70 years) with *P. vivax* malaria in the Brazilian Amazon [62], and experimental models of murine malaria in which reductions in PGE<sub>2</sub> are associated with more severe clinical outcomes [63–65]. Results presented here extend these previous findings by showing that perturbations in the COX-2-PGE<sub>2</sub> pathway are also important for influencing the erythropoietic cascade in children with SMA. In the current study, we observed that children with SMA were significantly younger than the non-SMA group. However, analyses of the association between bicyclo-PGE<sub>2</sub> levels and age revealed no significant relationships, suggesting that decreased levels of bicyclo-PGE<sub>2</sub> are not simply a product of age, but rather a true pathophysiological process.

Data presented here are consistent with the fact that PGE<sub>2</sub> is an important soluble factor for promoting efficient erythropoiesis [66–68]. In addition to erythropoietin (EPO) [69], PGE<sub>2</sub> plays a critical role in human erythroid development by augmenting both cellular maturation and Hb forma-




Figure 3. Bicyclo-PGE<sub>2</sub>/creatinine concentrations and COX-2 transcripts stratified according to pigment-containing monocytes (PCMs). A: Plasma bicyclo-PGE<sub>2</sub>/creatinine (pg/mg/mL) in children with malaria grouped according to PCM levels. PCM (-) = no PCMs; low =  $\leq 10\%$ ; moderate =  $>10$  and  $< 26.7\%$ ; and high =  $\geq 26.7\%$ . Differences across the groups were determined by Kruskal-Wallis test with post hoc comparisons performed by Mann-Whitney *U*-test. B: Urinary bicyclo-PGE<sub>2</sub>/creatinine (pg/mg/mL) in children with malaria grouped according to PCM levels. PCM (-) = no PCMs; low =  $\leq 10\%$ ; moderate =  $>10$  and  $< 26.7\%$ ; and high =  $\geq 26.7\%$ . Differences across the groups were determined by Kruskal-Wallis test with post hoc comparisons performed by Mann-Whitney *U*-test. C: Semiquantitative COX-2 transcript expression in children with malaria grouped according to PCM levels ( $n = 23$ ). COX-2 mRNA expression mean values (arbitrary units, AU) were normalized by expression over GAPDH mRNA mean values (endogenous control). Multivariate analyses performed by ANOVA with post hoc bivariate comparisons were performed using Student's *t*-test.

tion [70–74]. Previous studies also showed that PGE<sub>2</sub> is the predominant prostanoid released by human erythroblasts [75] and that RBCs both release and respond to physiological concentrations of PGE<sub>2</sub> [48,50,51,76]. Thus, the association between suppression of the COX-2-PGE<sub>2</sub> pathway, more severe anemia, and reduced erythropoietic responses reported here in children with malaria parallels the known actions of PGE<sub>2</sub> on erythroid maturation. Although previous studies show that EPO is elevated in children with malarial anemia, and is not likely the cause of ineffective erythropoiesis [77–80] in these children, this cannot be definitively ruled out as EPO was not determined in the current study.

The etiology of SMA is complex and multifactorial [21,67,81,82] and is characterized by increased lysis of infected and uninfected erythrocytes [6,7,9], inefficient erythropoiesis or dyserythropoiesis [10], and erythrocyte sequestration in the spleen [11,12]. A recent case-control study investigating hemolysis in Gabonese children with malaria found that both extravascular and intravascular hemolysis are important causal factors for reduced Hb concentrations in children with SMA [83]. In addition, consistent with our previous publication in Kenyan children [19], they also found that SMA was characterized by a low RPI [83]. In the current study, we found that a low RPI ( $< 2$ ) was associated with reduced systemic PGE<sub>2</sub> levels. Due to lack of sufficient volumes/quantities of samples that could not be obtained from the anemic children, with serious health complications, we were unable to perform comprehensive investigations on the link between the COX-2-PGE<sub>2</sub> pathway and intravascular and extravascular hemolysis. However, indirect markers of extravascular hemolysis such as significantly elevated spleen size [20] and monocytic pigment deposition in our cohort of children with SMA

suggest that extravascular hemolysis is an important etiology of SMA in this holoendemic transmission region. Furthermore, the rates of erythrophagocytosis were enhanced among children with SMA in this study, consistent with a previous report [83]. We are currently performing studies that include measures of erythrocyte turnover (e.g., LDH and neopterin) and erythrophagocytosis (measurement of CD35, 55, 59, C3c, and Annexin V) to expand the knowledge about how the COX-2-PGE<sub>2</sub> pathway mediates these important etiological causes of SMA.

A primary challenge in the current study was the lack of bone-marrow biopsies from the children, based on practical and ethical considerations. As such, we cannot definitively determine if the low RPI scores in the context of decreased PGE<sub>2</sub> levels is truly indicative of a suppressed erythropoietic response. Although we will likely not be able to obtain bone-marrow biopsies in the future, we are currently investigating the direct effects of PGE<sub>2</sub> on erythroid maturation in a novel in vitro model of erythropoiesis we have developed using CD34<sup>+</sup> stem cells [84]. These studies should provide important insight about the direct effects of PGE<sub>2</sub> on erythroid development.

Results from our laboratory [61,84] and others [85–87] have shown that *Pf*H<sub>z</sub> and *Pf*H<sub>z</sub>-derived inflammatory mediators suppress erythropoiesis. In addition, in vitro studies from our laboratories demonstrated that phagocytosis of *Pf*H<sub>z</sub> suppresses COX-2 gene products and PGE<sub>2</sub> in a time- and dose-dependent manner [88]. The current study extends these findings by showing a progressive decrease in COX-2 transcripts and systemic bicyclo-PGE<sub>2</sub>/creatinine levels with increasing deposition of naturally acquired monocytic *Pf*H<sub>z</sub>, suggesting that accumulation of *Pf*H<sub>z</sub> in monocytic cells may be an important mechanism through which COX-2 and PGE<sub>2</sub> levels are suppressed during a

malaria infection. Although reduced COX-2 expression in tissue macrophages could contribute to the lower levels of systemic bicyclo-PGE<sub>2</sub>/creatinine observed here, it was impossible to determine the impact of these cellular populations on PGE<sub>2</sub> levels as tissue biopsies were unavailable. In addition, based on the fact that there was exceedingly limited biological sample available from these anemic infants, we opted not to measure COX-1 transcript as this isoform is constitutively expressed and produces PGEs in the context of physiological homeostasis [89]. In addition, our previous results indicate that COX-1 transcriptional expression is not altered following the phagocytosis of PfHz by mononuclear cells [30]. Although it is unlikely that COX-1 contributed to the differences observed in systemic bicyclo-PGE<sub>2</sub>/creatinine levels in the clinical groups, this possibility cannot be definitively ruled out.

Since salicylates and acetaminophen (paracetamol) can suppress urinary production of PGE<sub>2</sub> [90,91], the current study did not include children with reported antipyretic use 2 weeks prior to enrollment. Although it is possible that some of the children were given antipyretics prior to seeking treatment at the hospital, and this was not accurately reported by their caregivers, it is important to note that salicylates and acetaminophen primarily reduce PGE<sub>2</sub> production through steric hindrance of the COX enzymatic site and have minimal effects on de novo COX-2 gene expression [92,93]. Thus, data presented here showing the reduction of COX-2 transcripts in children with SMA and the dose-dependent reduction in COX-2 message with increasing levels of monocytic PfHz accumulation would not be affected by antipyretic use. Additional studies aimed at measuring the exact concentrations of antipyretic metabolites and their association with PGE<sub>2</sub> production in children with malaria, however, is warranted and may offer further insight into potential mechanisms that could affect the COX-2-PGE<sub>2</sub> pathway.

In conclusion, based on the results presented here in Kenyan children from a holoendemic *P. falciparum* transmission region, along with our previous studies conducted in other geographic regions with differing malaria endemicities and in individuals with distinct genetic backgrounds [30,42–44,88], we propose that suppression of systemic PGE<sub>2</sub> is a universal mediator of malaria pathogenesis. We further propose that reduced levels of systemic PGE<sub>2</sub> during a malaria infection are mediated, at least in part, by phagocytosis of PfHz by leukocytes. Recent in vitro and in vivo results from our laboratory showed that suppression of COX-2-mediated PGE<sub>2</sub> production is associated with overproduction of TNF- $\alpha$  in children with malaria [88]. Interestingly, measurement of 25 cytokines and chemokines in the plasma of the children investigated here failed to show any significant associations between bicyclo-PGE<sub>2</sub>/creatinine levels and inflammatory mediators. Thus, the exact means by which reduced production of PGE<sub>2</sub> alters the erythropoietic cascade in malaria remains to be determined.

### Acknowledgments

The authors offer their sincere gratitude and appreciation to all parents, guardians, and children from the Siaya District community for their participation in this study. They also thank the staff at the University of New Mexico/KEMRI Laboratories and the Siaya District Hospital Management for their support during the study. These data presented are published with the permission and approval of the director of Kenya Medical Research Institute.

### References

- World Health Organization. World Malaria Report 2009. Geneva: World Health Organization; 2009.
- Rowe JA, Opi DH, Williams TN. Blood groups and malaria: Fresh insights into pathogenesis and identification of targets for intervention. *Curr Opin Hematol* 2009;16:480–487.
- Obonyo CO, Vulule J, Akhwale WS, et al. In-hospital morbidity and mortality due to severe malarial anemia in western Kenya. *Am J Trop Med Hyg* 2007;77:23–28.
- Ong'echa JM, Keller CC, Were T, et al. Parasitemia, anemia, and malarial anemia in infants and young children in a rural holoendemic *Plasmodium falciparum* transmission area. *Am J Trop Med Hyg* 2006;74:376–385.
- Zucker JR, Perkins BA, Jafari H, et al. Clinical signs for the recognition of children with moderate or severe anaemia in western Kenya. *Bull World Health Organ* 1997;75 (Suppl 1):97–102.
- Dondorp AM, Angus BJ, Chotivanich K, et al. Red blood cell deformability as a predictor of anemia in severe falciparum malaria. *Am J Trop Med Hyg* 1999;60:733–737.
- Dondorp AM, Chotivanich KT, Fucharoen S, et al. Red cell deformability, splenic function and anaemia in thalassaemia. *Br J Haematol* 1999;105:505–508.
- Egan AF, Fabucci ME, Saul A, et al. Aotus New World monkeys: Model for studying malaria-induced anemia. *Blood* 2002;99:3863–3866.
- Price RN, Simpson JA, Nosten F, et al. Factors contributing to anemia after uncomplicated falciparum malaria. *Am J Trop Med Hyg* 2001;65:614–622.
- Buffet PA, Safeukui I, Milon G, et al. Retention of erythrocytes in the spleen: A double-edged process in human malaria. *Curr Opin Hematol* 2009;16:157–164.
- Abdalla S, Weatherall DJ, Wickramasinghe SN, et al. The anaemia of *P. falciparum* malaria. *Br J Haematol* 1980;46:171–183.
- Phillips RE, Looareesuwan S, Warrell DA, et al. The importance of anaemia in cerebral and uncomplicated falciparum malaria: Role of complications, dyserythropoiesis and iron sequestration. *Q J Med* 1986;58:305–323.
- Bassat Q, Guinovart C, Sigauque B, et al. Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital. *Trop Med Int Health* 2009;14:1011–1019.
- Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. *N Engl J Med* 2005;352:39–47.
- Davenport GC, Ouma C, Hittner JB, et al. Hematological predictors of increased severe anemia in Kenyan children coinfecting with *Plasmodium falciparum* and HIV-1. *Am J Hematol* 2010;85:227–233.
- Otieno RO, Ouma C, Ong'echa JM, et al. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. *AIDS* 2006;20:275–280.
- Waitumbi JN, Kuypers J, Anyona SB, et al. Outpatient upper respiratory tract viral infections in children with malaria symptoms in Western Kenya. *Am J Trop Med Hyg* 2010;83:1010–1013.
- Were T, Davenport GC, Hittner JB, et al. Bacteremia in Kenyan children presenting with malaria. *J Clin Microbiol* 2011;49:671–676.
- Were T, Davenport GC, Yamo EO, et al. Naturally acquired hemozoin by monocytes promotes suppression of RANTES in children with malarial anemia through an IL-10-dependent mechanism. *Microbes Infect* 2009;11:811–819.
- Novelli EM, Hittner JB, Davenport GC, et al. Clinical predictors of severe malarial anaemia in a holoendemic *Plasmodium falciparum* transmission area. *Br J Haematol* 2010;149:711–721.
- Perkins DJ, Were T, Davenport GC, et al. Severe malarial anemia: Innate immunity and pathogenesis. *Int J Biol Sci* 2011;7:1427–1442.
- Krugliak M, Zhang J, Ginsburg H. Intraerythrocytic *Plasmodium falciparum* utilizes only a fraction of the amino acids derived from the digestion of host cell cytosol for the biosynthesis of its proteins. *Mol Biochem Parasitol* 2002;119:249–256.
- Liu J, Istvan ES, Gluzman IY, et al. *Plasmodium falciparum* ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. *Proc Natl Acad Sci USA* 2006;103:8840–8845.
- Chou AC, Fitch CD. Heme polymerase: Modulation by chloroquine treatment of a rodent malaria. *Life Sci* 1992;51:2073–2078.
- Egan TJ, Combrinck JM, Egan J, et al. Fate of haem iron in the malaria parasite *Plasmodium falciparum*. *Biochem J* 2002;365:343–347.
- Goldberg DE, Slater AF. The pathway of hemoglobin degradation in malaria parasites. *Parasitol Today* 1992;8:280–283.
- Pandey AV, Babbarwal VK, Okoyeh JN, et al. Hemozoin formation in malaria: A two-step process involving histidine-rich proteins and lipids. *Biochem Biophys Res Commun* 2003;308:736–743.
- Slater AF. Malaria pigment. *Exp Parasitol* 1992;74:362–365.
- Slater AF, Swiggard WJ, Orton BR, et al. An iron-carboxylate bond links the heme units of malaria pigment. *Proc Natl Acad Sci USA* 1991;88:325–329.
- Keller CC, Hittner JB, Nti BK, et al. Reduced peripheral PGE<sub>2</sub> biosynthesis in *Plasmodium falciparum* malaria occurs through hemozoin-induced suppression of blood mononuclear cell cyclooxygenase-2 gene expression via an interleukin-10-independent mechanism. *Mol Med* 2004;10:45–54.
- Habib A, Creminon C, Frobert Y, et al. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. *J Biol Chem* 1993;268:23448–23454.
- O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. *Proc Natl Acad Sci USA* 1992;89:4888–4892.
- Roy R, Polgar P, Wang Y, et al. Regulation of lysyl oxidase and cyclooxygenase expression in human lung fibroblasts: Interactions among TGF- $\beta$ , IL-1 $\beta$ , and prostaglandin E. *J Cell Biochem* 1996;62:411–417.
- Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and mac-

- rophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. *Cancer Res* 1998;58:1208–1216.
35. Krysan K, Reckamp KL, Dalwadi H, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. *Cancer Res* 2005;65:6275–6281.
  36. Machado ER, Carlos D, Lourenco EV, et al. Cyclooxygenase-derived mediators regulate the immunological control of *Strongyloides venezuelensis* infection. *FEMS Immunol Med Microbiol* 2010;59:18–32.
  37. Pino MS, Nawrocki ST, Cognetti F, et al. Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. *Cancer Biol Ther* 2005;4:1263–1269.
  38. Ramaswamy K, Kumar P, He YX. A role for parasite-induced PGE2 in IL-10-mediated host immunoregulation by skin stage schistosomula of *Schistosoma mansoni*. *J Immunol* 2000;165:4567–4574.
  39. Sato K, Torihashi S, Hori M, et al. Phagocytotic activation of muscularis resident macrophages inhibits smooth muscle contraction in rat ileum. *J Vet Med Sci* 2007;69:1053–1060.
  40. Granstrom E, Hamberg M, Hansson G, et al. Chemical instability of 15-keto-13,14-dihydro-PGE2: The reason for low assay reliability. *Prostaglandins* 1980;19:933–957.
  41. Murphy RC, FitzGerald GA. Current approaches to estimation of eicosanoid formation in vivo. *Adv Prostaglandin Thromboxane Leukot Res* 1994;22:341–348.
  42. Perkins DJ, Kremser PG, Weinberg JB. Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with *Plasmodium falciparum* malaria. *J Infect Dis* 2001;183:113–118.
  43. Perkins DJ, Hittner JB, Mwaikambo ED, et al. Impaired systemic production of prostaglandin E2 in children with cerebral malaria. *J Infect Dis* 2005;191:1548–1557.
  44. Perkins DJ, Moore JM, Otieno J, et al. In vivo acquisition of hemozoin by placental blood mononuclear cells suppresses PGE2, TNF- $\alpha$ , and IL-10. *Biochem Biophys Res Commun* 2003;311:839–846.
  45. Degousee N, Martindale J, Stefanski E, et al. MAP kinase kinase 6-p38 MAP kinase signaling cascade regulates cyclooxygenase-2 expression in cardiac myocytes in vitro and in vivo. *Circ Res* 2003;92:757–764.
  46. Jacobs-Helber SM, Ryan JJ, Sawyer ST. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. *Blood* 2000;96:933–940.
  47. Lasa M, Mahtani KR, Finch A, et al. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. *Mol Cell Biol* 2000;20:4265–4274.
  48. Rocca B, Secchiero P, Celeghini C, et al. Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. *Exp Hematol* 2004;32:925–934.
  49. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. *Blood* 2000;95:2391–2396.
  50. Li Q, Jungmann V, Kiyatkin A, et al. Prostaglandin E2 stimulates a Ca<sup>2+</sup>-dependent K<sup>+</sup> channel in human erythrocytes and alters cell volume and filterability. *J Biol Chem* 1996;271:18651–18656.
  51. Zamai L, Secchiero P, Pierpaoli S, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. *Blood* 2000;95:3716–3724.
  52. Bloland PB, Boriga DA, Ruebush TK, et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. *Am J Trop Med Hyg* 1999;60:641–648.
  53. Okiro EA, Alegana VA, Noor AM, et al. Changing malaria intervention coverage, transmission and hospitalization in Kenya. *Malar J* 2010;9:285.
  54. McElroy PD, Lal AA, Hawley WA, et al. Analysis of repeated hemoglobin measures in full-term, normal birth weight Kenyan children between birth and four years of age. III. The Asemobo Bay Cohort Project. *Am J Trop Med Hyg* 1999;61:932–940.
  55. WHO. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. *Trans R Soc Trop Med Hyg* 2000;94 (Suppl 1):S1–S90.
  56. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987;162:156–159.
  57. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. *Biophotonic Int* 2004;11:36–42.
  58. Luty AJ, Perkins DJ, Lell B, et al. Low interleukin-12 activity in severe *Plasmodium falciparum* malaria. *Infect Immun* 2000;68:3909–3915.
  59. Lyke KE, Diallo DA, Dicko A, et al. Association of intraleukocytic *Plasmodium falciparum* malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. *Am J Trop Med Hyg* 2003;69:253–259.
  60. Lee G. Anemia: General Aspects, 10th ed. Baltimore: Williams & Wilkins; 1999.
  61. Were T, Hittner JB, Ouma C, et al. Suppression of RANTES in children with *Plasmodium falciparum* malaria. *Haematologica* 2006;91:1396–1399.
  62. Andrade BB, Araujo-Santos T, Luz NF, et al. Heme impairs prostaglandin E2 and TGF- $\beta$  production by human mononuclear cells via Cu/Zn superoxide dismutase: Insight into the pathogenesis of severe malaria. *J Immunol* 2010;185:1196–1204.
  63. Ball HJ, MacDougall HG, McGregor IS, et al. Cyclooxygenase-2 in the pathogenesis of murine cerebral malaria. *J Infect Dis* 2004;189:751–758.
  64. Deininger MH, Kremser PG, Meyermann R, et al. Focal accumulation of cyclooxygenase-1 (COX-1) and COX-2 expressing cells in cerebral malaria. *J Neuroimmunol* 2000;106:198–205.
  65. Xiao L, Patterson PS, Yang C, et al. Role of eicosanoids in the pathogenesis of murine cerebral malaria. *Am J Trop Med Hyg* 1999;60:668–673.
  66. Datta MC. Prostaglandin E2 mediated effects on the synthesis of fetal and adult hemoglobin in blood erythroid bursts. *Prostaglandins* 1985;29:561–577.
  67. Lamikanra AA, Brown D, Potocnik A, et al. Malarial anemia: Of mice and men. *Blood* 2007;110:18–28.
  68. Ortega JA, Dukes PP, Ma A, et al. A clinical trial of prostaglandin E2 to increase erythropoiesis in anemia of end stage renal disease. A preliminary report. *Prostaglandins Leukot Med* 1984;14:411–416.
  69. Kendall RG. Erythropoietin. *Clin Lab Haematol* 2001;23:71–80.
  70. Boer AK, Drayer AL, Rui H, et al. Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. *Blood* 2002;100:467–473.
  71. Dukes PP, Shore NA, Hammond D, et al. Enhancement of erythropoiesis by prostaglandins. *J Lab Clin Med* 1973;82:704–712.
  72. Dupuis F, Desplat V, Praloran V, et al. Effects of lipidic mediators on the growth of human myeloid and erythroid marrow progenitors. *J Lipid Mediat Cell Signal* 1997;16:117–125.
  73. Lorenz M, Slaughter HS, Wescott DM, et al. Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. *Exp Hematol* 1999;27:1494–1502.
  74. Oonishi T, Sakashita K, Ishioka N, et al. Production of prostaglandins E1 and E2 by adult human red blood cells. *Prostaglandins Other Lipid Mediat* 1998;56:89–101.
  75. Rocca B, Secchiero P, Ciabattini G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. *Proc Natl Acad Sci USA* 2002;99:7634–7639.
  76. Allen JE, Rasmussen H. Human red blood cells: Prostaglandin E2, epinephrine, and isoproterenol alter deformability. *Science* 1971;174:512–514.
  77. Burchard GD, Radloff P, Philipps J, et al. Increased erythropoietin production in children with severe malarial anemia. *Am J Trop Med Hyg* 1995;53:547–551.
  78. Burgmann H, Looareesuwan S, Kapiotis S, et al. Serum levels of erythropoietin in acute *Plasmodium falciparum* malaria. *Am J Trop Med Hyg* 1996;54:280–283.
  79. Kurtzhals JA, Rodrigues O, Addae M, et al. Reversible suppression of bone marrow response to erythropoietin in *Plasmodium falciparum* malaria. *Br J Haematol* 1997;97:169–174.
  80. Nussenblatt V, Mukasa G, Metzger A, et al. Anemia and interleukin-10, tumor necrosis factor  $\alpha$ , and erythropoietin levels among children with acute, uncomplicated *Plasmodium falciparum* malaria. *Clin Diagn Lab Immunol* 2001;8:1164–1170.
  81. Casals-Pascual C, Roberts DJ. Severe malarial anaemia. *Curr Mol Med* 2006;6:155–168.
  82. Haldar K, Murphy SC, Milner DA, et al. Malaria: Mechanisms of erythrocytic infection and pathological correlates of severe disease. *Annu Rev Pathol* 2007;2:217–249.
  83. Fendel R, Brandts C, Rudat A, et al. Hemolysis is associated with low reticulocyte production index and predicts blood transfusion in severe malarial anemia. *PLoS One* 2010;5:e10038.
  84. Awandare GA, Kempaiah P, Ochiel DO, et al. Mechanisms of erythropoiesis inhibition by malarial pigment and malaria-induced proinflammatory mediators in an in vitro model. *Am J Hematol* 2011;86:155–162.
  85. Casals-Pascual C, Kai O, Cheung JO, et al. Suppression of erythropoiesis in malarial anemia is associated with hemozoin in vitro and in vivo. *Blood* 2006;108:2569–2577.
  86. Giribaldi G, Ulliers D, Schwarzer E, et al. Hemozoin- and 4-hydroxynonenal-mediated inhibition of erythropoiesis. Possible role in malarial dyserythropoiesis and anemia. *Haematologica* 2004;89:492–493.
  87. Lamikanra AA, Theron M, Kooij TW, et al. Hemozoin (malarial pigment) directly promotes apoptosis of erythroid precursors. *PLoS One* 2009;4:e8446.
  88. Keller CC, Davenport GC, Dickman KR, et al. Suppression of prostaglandin E2 by malaria parasite products and antipyretics promotes overproduction of tumor necrosis factor- $\alpha$ : Association with the pathogenesis of childhood malarial anemia. *J Infect Dis* 2006;193:1384–1393.
  89. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol* 1998;38:97–120.
  90. Bippi H, Frolich JC. Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man. *Br J Clin Pharmacol* 1990;29:305–310.
  91. Reimann IW, Golbs E, Fischer C, et al. Influence of intravenous acetylsalicylic acid and sodium salicylate on human renal function and lithium clearance. *Eur J Clin Pharmacol* 1985;29:435–441.
  92. Donnelly MT, Hawkey CJ. Review article: COX-II inhibitors—A new generation of safer NSAIDs? *Aliment Pharmacol Ther* 1997;11:227–236.
  93. Vane JR. NSAIDs, Cox-2 inhibitors, and the gut. *Lancet* 1995;346:1105–1106.